Replies to post #55930 on Avid Bioservices Inc (CDMO)

[north40000]

What Thurly said then is still in effect now, for both of us:

>>David Miller's Biotech Stock Research has written 18 pages on Perigrine in its Main Story for the newsletter this month. I can't talk about the content due to the licensing agreement, but for those of you who subscribe, it's worth the read.<<